MEF2C and breast carcinoma: Yang et al. illustrated that macrophages derived from monocytes treated with IL-4 produce exosomes containing larger amounts of miR-223 and inhibit the expression of myocyte-enhancing factor- 2c (Mef-2c) by binding to 2 target sites in 3′-UTR after transfer to a breast cancer cell.